While LNPs have not yet been applied to Wilson’s disease (WD), there are other examples of CRISPR-based gene editors for various liver diseases, such as Intellia Therapeutics’ NTLA-2001, which delivers mRNA-Cas9 to treat transthyretin amyloidosis caused by mutations in the TTR gene [307], and NTLA-2002 for the Hereditary Angioedema with the KLKB1 gene [308]. This evidence concerns the gene KLKB1 and Wilson disease.